Rural Teens Face Unique Cannabis Risks as Legalization Expands ↗
Review highlights overlooked cannabis risks for rural adolescents, including limited treatment access, unique demographics, and the shadow of the rural opioid crisis.
Browse more cannabis research, findings, methods, and limitations.
Review highlights overlooked cannabis risks for rural adolescents, including limited treatment access, unique demographics, and the shadow of the rural opioid crisis.
Scoping review finds cannabis use serves as meaningful occupation — supporting routines, identity, belonging — suggesting treatment should acknowledge what cannabis provides.
Chronic marijuana improved memory deficits and altered dopamine/cannabinoid receptor expression in a rat Parkinson disease model.
Pennsylvania medical cannabis patients used an average of 3.4 cannabis products alongside 3.7 other medications, with antidepressants and analgesics most common.
Repeated THC exposure in rats caused lasting, age-dependent changes in motivation and reward learning, with adult exposure showing stronger motivational enhancement.
Five-year systematic review of Canadian legalization: arrests down 75%, youth use stable, adult ER visits up 22%, pediatric edible hospitalizations up 7.5-fold. Neither catastrophe nor utopia.
Case report of a 39-year-old with undiagnosed schizoaffective disorder and heavy cannabis use who self-eviscerated during psychosis, requiring emergency surgery.
An estimated 1,245 children visited U.S. ERs in 2019-2020 after accidentally eating marijuana edibles, with most requiring hospital admission.
Cannabis-related ER visits among California adults 65+ surged 1,804% from 2005-2019, with older Black adults and those with more comorbidities most affected.
First-in-class CB1 signaling-specific inhibitor AEF0117 reduced cannabis positive effects by 38% and self-administration in early clinical trials for cannabis use disorder.
Rigorous Danish trial of 134 MS/SCI patients found no benefit of THC, CBD, or their combination over placebo for neuropathic pain or spasticity.
CBD relieves pain by directly blocking Cav3.2 calcium channels (independent of CB1), while THC-like drugs work through CB1 on different calcium channels.
MEPIRAPIM-derived compounds selectively blocked T-type calcium channels and reduced some seizure types but unexpectedly worsened absence epilepsy in rats.
Canadian young adults perceive cannabis as more harmful for 14-year-olds than for adults, with minimal perceived difference between use at 21 vs. 28 years old.
Cannabis users accurately predicted their driving impairment after THC inhalation — self-rated confidence correlated with actual simulator performance and THC dose.
Mouse study identifies microglial CB1 receptors as the mechanism by which adolescent THC causes social memory deficits, worsened by psychiatric risk gene 16p11.2 duplication.
Cannabis legalization drove greater CUD increases among VA patients with chronic pain than without, especially among those aged 65-75.
Survey of 4,328 cannabis users finds concentrate use 47% more likely in recreational law states and 29% more likely in medical-only states.
Lancet study of millions of VA patients finds cannabis legalization drives greater CUD increases in chronic pain patients, especially older adults.
Cannabis legalization modestly but significantly contributed to rising CUD among VA patients, with the strongest effect on adults aged 65-75.
Cochrane review of 14 studies finds moderate-certainty evidence that cannabis-based medicines are ineffective for opioid-refractory cancer pain.
Review links prenatal cannabis use to preterm birth, NICU admission, low birth weight, and small-for-gestational-age infants.
Rhesus macaque study shows chronic THC caused 59% testicular shrinkage, hormone disruption, and 23,558 sperm DNA changes, with only partial recovery after cessation.
CBDA-ME showed antidepressant effects in female rats through CB2 receptors, requiring higher doses than males and involving BDNF and endocannabinoid pathways.
Reddit analysis reveals the hemp industry wants self-regulation but lacks agreement on standards, leaving consumers experimenting with untested products.
Review proposes that CBD anti-inflammatory, vascular, and neuroprotective effects could theoretically benefit subarachnoid hemorrhage patients, pending research.
After MC became available in Arkansas, residents wanted less regulation and were less supportive of pharmacist involvement in cannabis safety.
Prospective study of 30 women with treatment-resistant fibromyalgia found significant quality of life improvements after 30 days of cannabis treatment.
Review identifies endocannabinoid metabolism inhibitors and receptor modulators as promising candidates for treating substance use, trauma, and autism disorders.
Synthetic cannabinoids are MAO-A-specific inhibitors, explaining severe cardiovascular side effects inconsistent with cannabinoid receptor activation.
ABCD Study data shows prenatal cannabis exposure effects on brain volume and visual processing may grow stronger as children develop from ages 9 to 13.
Danish study of 6.9 million people finds 15% of male schizophrenia cases attributable to cannabis use disorder, with young males at highest risk.
Even nonheavy marijuana use disrupted adolescent cognitive development in 5 of 8 domains, with amplified effects in youth with family history of schizophrenia.
Songbird study shows THC content critically modulates CBD efficacy for vocal recovery, with different effects on phonology versus syntax neural circuits.
Study of 3,991 German university students finds smoking, risky drinking, and marijuana use are strongly interconnected, suggesting integrated prevention approaches.
Study of 548 impaired driving cases shows two consecutive blood samples cannot reliably estimate THC levels at the time of driving due to analytical error.
First population study finds synthetic cannabinoids and CBD, not just cannabis, are associated with depression, anxiety, and hallucinations in UK teens aged 13-14.
In a clinical trial, 800 mg/day CBD prevented the anandamide decrease seen during cannabis cessation, but this change was not linked to clinical outcomes.
Cannabis users who had bariatric surgery lost equivalent weight to non-users at all time points through 2 years — the 'munchies' didn't undermine surgical outcomes.
Ethical framework for primary care: inform patients about cannabis driving risks, provide harm reduction, report when necessary, and maintain the therapeutic relationship.
Among 338,727 youth substance abuse cases (2000-2020), marijuana had the fastest-rising call rate, with edible products showing the most dramatic increase.
Peer acceptability of cannabis-impaired driving predicted 8x higher odds of the behavior in Washington young adults, stronger than alcohol-impaired driving norms.
Educational overview explains how cannabis affects brain development during pregnancy and adolescence, with prevention guidance for young people.
Case report: dronabinol (synthetic THC) resolved cannabinoid hyperemesis syndrome in a 21-year-old after haloperidol failed, demonstrating a paradoxical treatment approach.
Review of cannabinoids for neuromuscular disorders finds strongest evidence from MS pain/spasticity studies, with emerging evidence for other NMDs.
CBD protected astrocytes from inflammatory damage by boosting energy metabolism and reducing inflammatory cytokines, with CB1 receptors mediating the anti-inflammatory response.
CBD prevented osteoporosis in two mouse models and increased bone cell growth and osteogenic gene expression in human stem cells.
Ten-year study shows cannabis use after first psychosis selectively worsens diminished expression symptoms but not apathy.
Spanish hospital study of 341 first-episode psychosis patients finds cannabis use nearly doubles the risk of converting to schizophrenia within 5 years.
Well-controlled Australian cohort study found no association between prenatal marijuana exposure and neuropsychological deficits at age 10 or autistic traits at 19-20.